Results 91 to 100 of about 6,793 (233)

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC

open access: yesERJ Open Research, 2017
In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined.
Arsela Prelaj   +11 more
doaj   +1 more source

The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung

open access: yesCurrent Oncology, 2023
Large cell neuroendocrine carcinoma of the lung (LCNEC) is currently classified as a rare lung cancer subtype, but given the high incidence of lung cancer, the overall number of cases is considerable.
Catalin Buium   +3 more
doaj   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

open access: yes, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al   +21 more
core  

Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer

open access: yesCancer Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background Emerging evidence indicates that baseline use of certain concomitant drugs may affect the efficacy of immune checkpoint inhibitors (ICIs), including PD‐1, PD‐L1, and CTLA‐4 inhibitors, in patients with cancer. However, most previous studies have evaluated individual drug classes in isolation, without considering potential ...
Masafumi Saiki   +12 more
wiley   +1 more source

Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series

open access: yesCancer Reports, 2023
Background Large cell neuroendocrine tumors of the lung (LCNEC) are rare. Chemotherapy with the small cell lung carcinoma (SCLC) regimen is the most appropriate treatment for LCNEC.
Yutaka Takahara   +12 more
doaj   +1 more source

Enhancing Diagnostic Accuracy in Sinonasal Neuroendocrine Tumors: The Case for DOTATATE PET Over FDG PET

open access: yesInternational Forum of Allergy &Rhinology, Volume 15, Issue 10, Page 1023-1027, October 2025.
ABSTRACT Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms that arise from neuroendocrine cells and commonly originate in the GI tract, lungs, and pancreas, but can also present in the skull base and paranasal sinuses. While fluorodeoxyglucose positron emission tomography (FDG PET) scans are routinely used in the evaluation of ...
Michael Sabbaj   +12 more
wiley   +1 more source

Differences in Endoscopic Features of Gastric Neuroendocrine Tumor and Neuroendocrine Carcinoma From a Clinicopathological Perspective

open access: yesJGH Open, Volume 9, Issue 9, September 2025.
ABSTRACT Gastric neuroendocrine neoplasms are a rare type of stomach cancer, classified into well‐differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Gastric NETs (G‐NETs) originate from endocrine progenitor cells in the basal layer of the mucosa, primarily in the setting of chronic atrophic gastritis,
Katsunori Matsueda   +4 more
wiley   +1 more source

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

open access: yesFrontiers in Medicine
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma (HGNEC) accounting for 3% of primary lung cancer, and characterized by strong invasion, high heterogeneity, and extremely poor prognosis.
Siyu Zhu   +10 more
doaj   +1 more source

Diagnosing Malignant Epithelial Neoplasms of the Lung in Cytological Specimens: Cytomorphology, Ancillary Studies and Management

open access: yesCytopathology, Volume 36, Issue 5, Page 467-478, September 2025.
This review provides an overview of the key cytopathological features defining the ‘Malignant’ category of the World Health Organization's Reporting System for Lung Cytopathology and discusses the application of ancillary techniques in cytological specimens from the lung, including immunocytochemistry and molecular testing.
Magdalena M. Brune   +3 more
wiley   +1 more source

Pain Flare After Single Fraction Radiotherapy for Symptomatic Bone Metastases—Do We Have a Predictive Model?

open access: yesCancer Medicine, Volume 14, Issue 16, August 2025.
ABSTRACT Background The COVID‐19 pandemic reintroduced single‐fraction radiotherapy for symptomatic bone metastases due to its efficiency, rapid realization, and cost‐effectiveness. However, pain flare can occur as a side effect that can have a significant impact on a patient's quality of life.
Tatjana Arsenijević   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy